Male mice treated with combined anti-fibrotic therapeutics, IPW5371 and tadalafil, are predisposed to adverse cardiovascular events
Rattachement africain : us, au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Fibrosis is a pathological process with few therapeutic options. Experimental molecules are being developed to counteract the fibrotic effects through TGFβ receptor inhibition. Additionally, phosphodiesterase 5 (PDE5) inhibitors also have anti-fibrotic effects; however, the mechanism of action remains unresolved. IPW5371 is an example of an experimental TGFβ-mediated anti-fibrotic compound, and tadalafil is an example of a PDE5 inhibitor. Irradiation increases the frequency of fibrotic lesions, driven by the activation of the TGFβ pathway. We hypothesized that the TGFβ receptor and PDE5 inhibitor agents would be additive in their ability to prevent fibrosis development in tissues in a sub-lethal whole-body irradiation mouse model. However, the combined use of anti-fibrotic agents, tadalafil and IPW5371, caused increased male mouse mortality associated with ascending and thoracic aortic rupture compared to mice that only received one of the drugs. Following histopathological analysis of the mouse hearts, we also observed that irradiation protected against lesions caused by the combination therapy as non-irradiated male mice had significantly worse outcomes as compared to irradiated male mice, substantiating the drug-drug interaction independent of the radiation effects. This important drug interaction needs further investigation as these agents are developed for anti-fibrosis therapy, and PDE5 inhibitors are commonly prescribed to male patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Male mice treated with combined anti-fibrotic therapeutics, IPW5371 and tadalafil, are predisposed to adverse cardiovascular events
- Date Crossref
- 02/04/2025
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of North Carolina at Chapel Hill Division of Comparative Medicine and Department of Pathology and Laboratory Medicine pays non établi dans la noticeUniversité ou école supérieure
-
NC Department of Health and Human Services pays non établi dans la noticeOrganisme public
-
University of Georgia pays non établi dans la noticeUniversité ou école supérieure
-
Wake Forest University pays non établi dans la noticeUniversité ou école supérieure
-
Innovation Pathways pays non établi dans la noticeEntreprise
-
University of Tasmania pays non établi dans la noticeUniversité ou école supérieure
-
College of Veterinary Medicine Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
-
Wake Forest School of Medicine Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
-
StageBio pays non établi dans la noticeInstitution
-
College of Health and Medicine pays non établi dans la noticeUniversité ou école supérieure
Division of Comparative Medicine and Department of Pathology and Laboratory Medicine — University of North Carolina at Chapel Hill, NC Department of Health and Human Services et University of Georgia, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.